Between 2002 and 2005, Andrew was President of Pall Asia, a subsidiary of Pall Corporation, with responsibility for all Pall Corporation activities in the Asia Pacific region.

Andrew joined Pall in 2002 with the acquisition by Pall Corporation of US Filter’s Filtration and Separations business, where he was President. Andrew was appointed President and Chief Operating Officer of the US Filter Filtration and Separations Group in February 1998 after US Filter acquired Memtec Limited. Prior to his position at US Filter, Andrew was President and Chief Operating Officer of Memtec Limited from 1987 to 1997, and prior to that, at Baxter Healthcare Corporation where he was employed for 12 years in a number of positions. Andrew’s last assignment at Baxter Healthcare Corporation was as President of the corporation’s US based Medical Devices Division.

Andrew is Chairman of Universal Biosensors Inc., and a non executive Director of Cochlear Ltd and Vaxxas Pty Ltd.

Andrew graduated from the University of Manchester with a Bachelor of Science Degree (Honours) in Chemistry and achieved a distinction in his MBA at the Harvard Business School and is a Fellow of the Australian Institute of Company Directors. Andrew was appointed as a Director of SpeeDx Pty Ltd in 2009.


Non Executive Director

Andy is a Managing Director with Talu Ventures in Brisbane, Australia. Talu Ventures was founded in 2013 with a portfolio of investments formerly managed by CM Capital Investments. Andy joined CM Capital Investments in 2003 and spent 7 years as a Partner in the firm. Andy has more than 20 years of experience in the biomedical and IT industries. Following 4 years as a Project Manager at the CSIRO, Andy spent 5 years at AGEN Biomedical in various project management and business development roles. He joined Lake Technology, Sydney, in 1999, prior to its ASX listing, as Director of Business Development & Licensing. Lake Technology was later acquired by Dolby Labs in 2003. Andy is a current Board member of Universal Biosensors Pty (ASX: UBI), Osprey Medical (ASX: OSP), Advent Pharmaceuticals Pty, Altiris Pharmaceuticals Inc and Piedmont Pharmaceuticals Inc.

Andy has a BSc Hons degree in Physics from the University of St Andrews in Scotland. He also has a Master of Science degree in Instrumentation from the University of Manchester. Andy has a Diploma of Financial Services (Financial Markets) from AFMA and a post-grad Certificate in Science Media & Journalism from the University of Technology in Sydney.


Non Executive Director

John Klopp was Worldwide Vice President, Business Development, for Johnson & Johnson’s Diabetes Care Franchise when he retired in 2009. During his sixteen year career with J&J, he established several partnerships with other companies, led the acquisition of two publicly traded companies, and led several successful patent legal actions. The acquisitions represented over 90% of the Diabetes Care Franchise sales in 2009.

Prior to Johnson & Johnson, he was Manager of Licenses and Acquisitions for DuPont Medical Products Department. During his 28 year career with DuPont, he held positions of increasing responsibility in New Venture Development, turnarounds, partnership and joint venture development, and M&A. After the formation of a joint venture with Applied BioTechnology (Inc.), he was elected to the Board of ABT.

In 2010, he was appointed to the Research and Development Committee of the Juvenile Diabetes Research Foundation. He received B.S. and M.S. degrees in Chemical Engineering from Oklahoma State University. John was appointed as a Director of SpeeDx Pty Ltd in 2010.